There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Actinium Pharmaceuticals (ATNM – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report) with bullish sentiments.
Actinium Pharmaceuticals (ATNM)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals, with a price target of $50.00. The company’s shares closed last Monday at $8.51.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $30.50, representing a 289.5% upside. In a report issued on March 19, JonesTrading also maintained a Buy rating on the stock with a $26.00 price target.
See today’s best-performing stocks on TipRanks >>
Centessa Pharmaceuticals (CNTA)
In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $15.00. The company’s shares closed last Monday at $10.93.
According to TipRanks.com, Biliouris is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Centessa Pharmaceuticals with a $13.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATNM:
- Actinium Pharmaceuticals’ Iomab-ACT included in CAR T-Cell therapy study
- Biotech Alert: Searches spiking for these stocks today
- This radiopharma name seen as ‘poised for takeout’ following Fusion deal
- Actinium Pharmaceuticals price target raised to $30 from $20 at Maxim
- Actinium positioned for takeout after Fusion deal, says H.C. Wainwright
